Browse drugs

…ion frequency and mean treatment cost per patient compared with AFLI2, enabling longer treatment intervals through treat-and-extend r…

…cuity, ocular pain, and blurred vision.Conclusion and Relevance Aflibercept 8 mg/0.07 mL showed effective outcomes and good tolerance in bo…

… (95% CI) difference of −6.53 (−12.47 to −0.58 µm) in favour of ranibizumab (23.53 (18.58 to 28.49) µm) versus aflibercept (30.06 (25.04 to…

… Retinopathy Study letters at 12 months.Conclusion Switching to aflibercept 8 mg substantially reduced the proportion of eyes on short inte…

…f aflibercept 8 mg (AFL-8) compared to faricimab 6 mg (FAR) and aflibercept 2 mg (AFL-2).Material and Methods Clinical trial data of phase …

… and biosimilar ranibizumab, aflibercept 2 mg, brolucizumab and faricimab—across three dosing regimens: fixed, Pro Re Nata and Treat-and-…

…otal of 3,223 patients received 31,826 intravitreal injections. Bevacizumab was the most frequently prescribed drug (58.73%, n=18,690), fol…

…r centre’s experience.Aim and Objectives To evaluate the use of faricimab and its economic impact from the hospital pharmacy perspective.…

…tervals than with previous anti-VEGF therapies, indicating that faricimab is effective for individualised dosing in real-world settings. …

…ltiple anti-VEGF agents, including ranibizumab, aflibercept and faricimab, over 19 months. Despite ongoing therapy, her SRF persisted and…

… MYL-1701P and those who switched from reference aflibercept to MYL-1701P in the 20-week extension study of the pivotal trial.Trial regis…

…cizumab MVASI (25 mg/mL), ranibizumab Ranivisio (0.6 mg/mL) and faricimab Vabysmo (120 mg/mL) stored in silicone-free and oil-free polypropylene …